Search

Your search keyword '"Volckaert, Bram"' showing total 7 results
Start Over Author "Volckaert, Bram"
7 results on '"Volckaert, Bram"'

1. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Author

Johns, Douglas G., Campeau, Louis-Charles, Banka, Puja, Bautmans, An, Bueters, Tjerk, Bianchi, Elisabetta, Branca, Danila, Bulger, Paul G., Crevecoeur, Inne, Ding, Fa-Xiang, Garbaccio, Robert M., Guetschow, Erik D., Guo, Yan, Ha, Sookhee N., Johnston, Jennifer M., Josien, Hubert, Kauh, Eunkyung A., Koeplinger, Kenneth A., Kuethe, Jeffrey T., Lai, Eseng, Lanning, Christine L., Lee, Anita Y.H., Li, Li, Nair, Anilkumar G., O’Neill, Edward A., Stoch, S. Aubrey, Thaisrivongs, David A., Tucker, Thomas J., Vachal, Petr, van Dyck, Kristien, Vanhoutte, Frederic P., Volckaert, Bram, Wolford, Dennis G., Xu, Andy, Zhao, Tian, Zhou, Dan, Zhou, Susan, Zhu, Xiaohong, Zokian, Hratch J., Walji, Abbas M., and Wood, Harold B.

Published
2023
Full Text
View/download PDF

2. First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα

Author

Poirier, Nicolas, primary, Baccelli, Irène, additional, Belarif, Lyssia, additional, Abès, Riad, additional, Teppaz, Géraldine, additional, Mary, Caroline, additional, Poli, Sonia, additional, Fromond, Claudia, additional, Girault, Isabelle, additional, Pengam, Sabrina, additional, Soma, Emilienne, additional, De Sa, Fanny, additional, Conduzorgues, Jean-Pascal, additional, Braudeau, Cécile, additional, Josien, Regis, additional, Volckaert, Bram, additional, Costantini, Dominique, additional, and Corallo, Frédérique, additional

Published
2023
Full Text
View/download PDF

3. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study

Author

Gevaert, Philippe, primary, De Craemer, Jarno, additional, De Ruyck, Natalie, additional, Rottey, Sylvie, additional, de Hoon, Jan, additional, Hellings, Peter W., additional, Volckaert, Bram, additional, Lesneuck, Kristof, additional, Orengo, Jamie M., additional, Atanasio, Amanda, additional, Kamal, Mohamed A., additional, Abdallah, Hisham, additional, Kamat, Vishal, additional, Dingman, Robert, additional, DeVeaux, Michelle, additional, Ramesh, Divya, additional, Perlee, Lorah, additional, Wang, Claire Q., additional, Weinreich, David M., additional, Herman, Gary, additional, Yancopoulos, George D., additional, and O’Brien, Meagan P., additional

Published
2022
Full Text
View/download PDF

4. M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain

Author

Eiden, Joseph, primary, Volckaert, Bram, additional, Rudenko, Oleg, additional, Aitchison, Roger, additional, Herber, Renee, additional, Belshe, Robert, additional, Greenberg, Harry, additional, Coelingh, Kathleen, additional, Marshall, David, additional, Kawaoka, Yoshihiro, additional, Neumann, Gabriele, additional, and Bilsel, Pamuk, additional

Published
2021
Full Text
View/download PDF

5. M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.

Author

Eiden, Joseph, Volckaert, Bram, Rudenko, Oleg, Aitchison, Roger, Herber, Renee, Belshe, Robert, Greenberg, Harry, Coelingh, Kathleen, Marshall, David, Kawaoka, Yoshihiro, Neumann, Gabriele, and Bilsel, Pamuk

Subjects
*INFLUENZA vaccines, *IMMUNOGLOBULINS, *INFLUENZA, *IMMUNITY, *RESEARCH funding, *VIRAL antibodies, *INFLUENZA A virus, H1N1 subtype, *INFLUENZA A virus, H3N2 subtype
Abstract

Background: Current influenza vaccines are strain specific and demonstrate low vaccine efficacy against H3N2 influenza disease, especially when vaccine is mismatched to circulating virus. The novel influenza vaccine candidate, M2-deficient single replication (M2SR), induces a broad, multi-effector immune response.Methods: A phase 2 challenge study was conducted to assess the efficacy of an M2SR vaccine expressing hemagglutinin and neuraminidase from A/Brisbane/10/2007 (Bris2007 M2SR H3N2; clade 1). Four weeks after vaccination, recipients were challenged with antigenically distinct H3N2 virus (A/Belgium/4217/2015, clade 3C.3b) and assessed for infection and clinical symptoms.Results: Adverse events after vaccination were mild and similar in frequency for placebo and M2SR recipients. A single dose of Bris2007 M2SR induced neutralizing antibody to the vaccine (48% of recipients) and challenge strain (27% of recipients). Overall, 54% of M2SR recipients were infected after challenge, compared with 71% of placebo recipients. The subset of M2SR recipients with a vaccine-induced microneutralization response against the challenge virus had reduced rates of infection after challenge (38% vs 71% of placebo recipients; P = .050) and reduced illness.Conclusions: Study participants with vaccine-induced neutralizing antibodies were protected against infection and illness after challenge with an antigenically distinct virus. This is the first demonstration of vaccine-induced protection against a highly drifted H3N2 challenge virus. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. 2748. Single Intranasal (IN) Dose of M2SR (M2-Deficient Single Replication) Live Influenza Vaccine Protects Adults Against Subsequent Challenge with a Substantially Drifted H3N2 Strain

Author

Eiden, Joseph, primary, Volckaert, Bram, additional, Rudenko, Oleg, additional, Ellis, Ruth, additional, Aitchison, Roger, additional, Herber, Renee, additional, Belshe, Robert, additional, Greenberg, Harry, additional, Coelingh, Kathleen, additional, Kawaoka, Yoshihiro, additional, Neumann, Gabriele, additional, and Bilsel, Pamuk, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results